Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study
NCT07298408
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetic Peripheral Neuropathic Pain (DPN)
- Diabetic Neuropathies
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Florida A&M University
- Last updated on ClinicalTrials.gov
- April 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- the FSU TMH Family Practice Residency Program · Tallahassee, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.